(-)-Arctigenin: Mechanistic Insights into an Anti-Inflammatory and Antiviral Agent

Executive Summary: (-)-Arctigenin is a bioactive natural product with high purity (>98%) and multiple pharmacological actions, including suppression of NF-κB (p65) signaling and inhibition of MEK1 with an IC₅₀ of 0.5 nM [Product].
It inhibits inducible nitric oxide synthase (iNOS) expression in response to LPS via blockade of IκBα phosphorylation and p65 nuclear translocation (IC₅₀ = 10 nM) [Li et al. 2022].
(-)-Arctigenin demonstrates in vitro inhibition of HIV-1 replication and provides neuroprotection through kainate receptor binding [Internal].
The compound is insoluble in water and ethanol but dissolves in DMSO at ≥17.2 mg/mL; recommended storage is desiccated at -20°C [Product].
Recently, its ability to disrupt tumor-associated macrophage (TAM)-mediated NF-κB activation in breast cancer microenvironments has been highlighted, extending its translational potential [Li et al. 2022].

Biological Rationale

NF-κB and MAPK/ERK signaling pathways are central to inflammatory response, oncogenic transformation, and viral pathogenesis [Li et al. 2022]. Aberrant activation of these pathways is observed in tumor-associated macrophages (TAMs), facilitating metastasis and immunosuppression in cancers such as breast cancer. MicroRNAs (e.g., miR-660) within TAM-derived extracellular vesicles can upregulate NF-κB (p65) signaling by targeting KLHL21, thereby promoting tumor progression. Targeted inhibition of these pathways is a validated strategy for anti-inflammatory, antiviral, and anti-cancer interventions. (-)-Arctigenin, a lignan isolated from plants such as Arctium lappa, is structurally (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one with formula C₂₁H₂₄O₆ and molecular weight 372.41 [Product]. Its multifaceted inhibitory actions make it a strong candidate for translational research targeting these molecular axes.

Mechanism of Action of (-)-Arctigenin

(-)-Arctigenin acts through several defined molecular mechanisms:

• NF-κB Pathway Inhibition: It blocks IκBα phosphorylation and prevents p65 nuclear translocation, thereby reducing inducible nitric oxide synthase (iNOS) gene expression in response to LPS stimulation. This effect occurs at concentrations as low as 10 nM [Li et al. 2022].
• MEK1 (MAPK/ERK Kinase) Inhibition: (-)-Arctigenin directly inhibits MEK1 activity (IC₅₀ = 0.5 nM), thereby suppressing downstream ERK1/2 phosphorylation and cell proliferation signals [Internal].
• Kainate Receptor Binding: The molecule binds kainate receptors in neuronal cells, contributing to neuroprotection against excitotoxicity [Internal].
• Antiviral Action: In vitro assays show the compound inhibits HIV-1 replication, although the precise molecular target remains under investigation [Product].

These combined actions allow (-)-Arctigenin to modulate key cellular events implicated in inflammation, viral infection, and tumor progression.

Evidence & Benchmarks

• (-)-Arctigenin suppresses LPS-induced iNOS expression in macrophages by inhibiting NF-κB p65 nuclear translocation (IC₅₀ = 10 nM) (Li et al. 2022).
• The compound directly inhibits MEK1 kinase activity with an IC₅₀ of 0.5 nM in cell-free systems (Internal Article).
• In vitro, (-)-Arctigenin reduces HIV-1 replication, as measured by viral load assays (Product Page).
• Demonstrates neuroprotective effects via binding to kainate receptors in rodent brain tissue models (Internal Article).
• Product is supplied at >98% purity with quality control by HPLC, NMR, and MSDS (Product Page).
• Recent studies highlight (-)-Arctigenin's ability to counteract TAM-mediated breast cancer progression by interrupting the KLHL21/IKKβ/NF-κB p65 axis (Li et al. 2022).

This article extends the detailed mechanism-of-action analysis from "(-)-Arctigenin: Next-Generation Modulator of Tumor Microe..." by integrating new clinical research on TAM signaling and breast cancer metastasis. For translational guidance, see "Translating Mechanistic Insight into Impact: (-)-Arctigen...", which this article updates with fresh benchmarks. Workflow integration strategies are detailed further in "Applied Research Strategies with (-)-Arctigenin: From Ben...", whereas this piece clarifies product-specific handling and limits.

Applications, Limits & Misconceptions

(-)-Arctigenin is primarily used as a research tool for interrogating inflammatory, oncogenic, and viral pathways. Its robust inhibition of iNOS, MEK1, and NF-κB makes it valuable in cell signaling and tumor microenvironment studies. However, key boundaries should be noted.

Common Pitfalls or Misconceptions

• Not a clinical drug: (-)-Arctigenin is not FDA-approved for therapeutic use in humans; all data are preclinical.
• Solubility Constraints: It is insoluble in water and ethanol; use DMSO (≥17.2 mg/mL) for stock solutions.
• Storage Recommendations: Long-term storage of solutions is not advised; store powder desiccated at -20°C.
• Specificity Limits: While potent, its effects on kinases or receptors outside MEK1 and kainate family have not been exhaustively mapped.
• Not effective in all cellular contexts: Efficacy may vary with cell type, assay conditions, or genetic background; always benchmark with controls.

Workflow Integration & Parameters

For optimal experimental use, (-)-Arctigenin (SKU: N2399) should be reconstituted in DMSO to a working concentration matched to the target assay (commonly 10–500 nM for signaling inhibition studies). Quality control data (HPLC, NMR, MSDS) are supplied with each batch, facilitating reproducibility. Ensure storage at -20°C in desiccated conditions and minimize freeze-thaw cycles. For mechanistic dissection of NF-κB or MAPK/ERK pathways, pair (-)-Arctigenin with transcriptomics or phosphoproteomics endpoints. The product’s high purity supports quantitative and qualitative assays in oncology, immunology, and virology research.

Conclusion & Outlook

(-)-Arctigenin is a well-characterized, high-purity natural product that robustly inhibits key signaling pathways implicated in inflammation, cancer, and viral replication. Its dual action as a MEK1 inhibitor and iNOS expression blocker provides mechanistic leverage for translational research, especially in the context of tumor microenvironment modulation. While not approved for clinical use, its specificity and potency make it a preferred reagent for bench-to-bedside discovery in molecular biology and oncology. For further technical documentation and purchase options, see the product page.